Autopsy report · NCT05417893

Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions

“Operational and feasibility constraints due to regulatory requirements”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Meril Life Sciences Pvt. Ltd.

Sponsor type

Industry

Conditions

Coronary Artery Disease

Interventions

MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)

Participants

0

Trials that died the same way

• Point of Care Ultrasound in Obstetric Triage
  “Feasibility issue at institution” (61% match in meaning)
• ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
  “Due to operational and regulatory considerations.” (59% match in meaning)
• Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
  “Operational challenges” (58% match in meaning)
• NOA-12: BIBF1120 and R-RT in Glioblastoma
  “Interim Analysis for Feasibility” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.